• Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

    ソース: Nasdaq GlobeNewswire / 02 11 2021 06:00:00   America/New_York

    SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30, 2021.

    Recent Highlights

    • Initiated a strategic partnership with Abcam, a world leader in the design and production of commercial antibodies, which we expect to accelerate our technology development pipeline and provide access to antibody development expertise that we believe will enhance protein detection in our platform.
    • Signed our second and third research collaborations, one with a global pharmaceutical company and the other with an investigator at The University of Texas MD Anderson Cancer Center. Both collaborations are expected to utilize the Nautilus platform across a number of projects to investigate proteins and proteoforms of interest.
    • Shared a manuscript that introduces the theoretical foundation for a fundamentally different approach to proteomics, called Protein Identification by Short-epitope Mapping (PrISM).

    “Reflecting on the year thus far, 2021 has been characterized by exciting collaboration agreements, momentum around planned publications, the initiation of strategic partnerships, and our move to new world-class facilities in both San Carlos and Seattle,” said Sujal Patel, CEO of Nautilus. “Our team of scientific and engineering innovators continues to execute and capitalize on a wide range of opportunities. I am very proud of the team and pleased with the progress we are making towards delivering a deeper, richer view of the proteome than ever before possible.”

    Third Quarter 2021 Financial Results

    Operating expenses were $14.6 million for the third quarter of 2021, a 262% increase from $4.0 million for the three months ended September 30, 2020. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products as well as the costs associated with being a public company.

    Net loss was $14.5 million for the third quarter of 2021, as compared to a net loss of $4.0 million for the corresponding prior year period.

    Cash, cash equivalents, and investments were $374.0 million as of September 30, 2021.

    Webcast and Conference Call Information

    Nautilus will host a conference call to discuss the third quarter 2021 financial results, business developments and outlook before market open on Tuesday, November 2nd, 2021 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

    About Nautilus Biotechnology, Inc.

    Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

    Special Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding our collaborations and strategic partnerships, including our expectations with respect to the suitability of the Nautilus product platform to investigate proteins and proteoforms, and the ability of our strategic partnership to accelerate technology development and enhance protein detection; and expectations with respect to the functionality and performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in the Registration Statement on Form S-1 filed with the SEC as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2021. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Disclosure Information

    Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

    Media Contact
    Thermal for Nautilus Biotechnology
    Kaustuva Das
    press@nautilus.bio

    Investor Contact
    investorrelations@nautilus.bio


    Nautilus Biotechnology, Inc.
    Condensed Consolidated Balance Sheets
    As of September 30, 2021 and December 31, 2020 (Unaudited)

    (in thousands)September 30,
    2021
     December 31,
    2020
    Assets   
    Current assets:   
    Cash and cash equivalents$190,241  $36,607 
    Short-term investments157,104  40,135 
    Prepaid expenses and other current assets4,877  917 
    Total current assets352,222  77,659 
    Property and equipment, net2,046  1,371 
    Operating lease right-of-use assets3,685  4,842 
    Long-term investments26,627   
    Other long term assets767  1,139 
    Total assets$385,347  $85,011 
    Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity (Deficit)   
    Current liabilities:   
    Accounts payable$1,498  $470 
    Accrued expenses and other liabilities2,397  1,069 
    Current portion of operating lease liability314  1,479 
    Total current liabilities4,209  3,018 
    Operating lease liability, net of current portion3,291  3,296 
    Total liabilities7,500  6,314 
    Redeemable convertible preferred stock:   
    Series Seed redeemable convertible preferred stock  5,494 
    Series A redeemable convertible preferred stock  27,067 
    Series B redeemable convertible preferred stock  75,857 
        
    Stockholders’ equity (deficit):   
    Preferred stock   
    Common stock12  1 
    Additional paid-in capital441,795  600 
    Accumulated other comprehensive (loss) income(9) 3 
    Accumulated deficit(63,951) (30,325)
    Total stockholders’ equity (deficit)377,847  (29,721)
    Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)$385,347  $85,011 


    Nautilus Biotechnology, Inc.
    Condensed Consolidated Balance Sheets
    As of September 30, 2021 and December 31, 2020 (Unaudited)

     Three Months Ended September 30, Nine Months Ended September 30,
    (in thousands, except share and per share amounts)2021 2020 2021 2020
    Operating expenses       
    Research and development$8,244  $3,317  $19,459  $8,538 
    General and administrative6,324  710  14,223  1,886 
    Total operating expenses14,568  4,027  33,682  10,424 
    Other income (expense), net64  49  56  157 
    Net loss$(14,504) $(3,978) $(33,626) $(10,267)
    Net loss per share attributable to common stockholders, basic and diluted$(0.12) $(0.13) $(0.47) $(0.36)
    Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted124,114,893  29,963,812  71,062,172  28,208,770 

    (1)   The weighted-average number of shares of Common Stock outstanding prior to the Business Combination have been retroactively restated to reflect the exchange ratio of approximately 3.6281 established in the Business Combination.


    Nautilus Biotechnology, Inc.
    Condensed Consolidated Statements of Operations
    Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)

     Nine Months Ended September 30,
    (in thousands)2021 2020
    Cash flows from operating activities   
    Net loss$(33,626) $(10,267)
    Adjustments to reconcile net loss to net cash used in operating activities   
    Depreciation756  516 
    Stock-based compensation5,404  119 
    Net amortization of premiums on securities190  179 
    Amortization of operating lease right-of-use assets1,217  1,232 
    Changes in operating assets and liabilities:   
    Prepaid expenses and other assets(3,860) (318)
    Accounts payable887  57 
    Accrued expenses and other liabilities1,533  399 
    Operating lease liability(1,223) (1,186)
    Net cash used in operating activities(28,722) (9,269)
    Cash flows from investing activities   
    Proceeds from sale and maturities of securities40,000  15,001 
    Purchases of securities(183,745) (68,359)
    Purchases of property and equipment(1,283) (617)
    Net cash used in investing activities(145,028) (53,975)
    Cash flows from financing activities   
    Net proceeds from reverse recapitalization and PIPE financing335,409   
    Payments of deferred offering costs(8,129)  
    Proceeds from exercise of stock options104  32 
    Proceeds from issuance of convertible preferred stock, net of issuance costs  75,857 
    Net cash provided by financing activities327,384  75,889 
    Net increase in cash, cash equivalents and restricted cash153,634  12,645 
        
    Cash, cash equivalents and restricted cash at beginning of period37,219  595 
    Cash, cash equivalents and restricted cash at end of period$190,853  $13,240 

    Primary Logo

シェアする